Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6741-6750

  Zannella, Vanessa E ^a,c   Pra, Alan Dal ^a,b,c   Muaddi, Hala ^a,c   McKee, Trevor D ^a   Stapleton, Shawn ^a,c   Sykes, Jenna ^a   Glicksman, Rachel ^b,c   Chaib, Selim ^a,e   Zamiara, Paul ^a,c   Milosevic, Michael ^a,b,c   Wouters, Bradly G ^a,c,d,e   Bristow, Robert G ^a,b,c   Koritzinsky, Marianne ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE; METFORMIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER INHIBITION; CANCER STAGING; CLONOGENIC ASSAY; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; OXYGENATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION RESPONSE; RETROSPECTIVE STUDY; TUMOR HYPOXIA; TUMOR OXYGENATION; TUMOR XENOGRAFT;

ANIMALS; CELL HYPOXIA; COLORECTAL NEOPLASMS; ELECTRON TRANSPORT COMPLEX I; HCT116 CELLS; HUMANS; MALE; METFORMIN; MICE; OXYGEN; OXYGEN CONSUMPTION; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890642780     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1787     Document Type: Article

References (37)

1. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24. (Pubitemid 41503384)
2. Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012;18:2108-14.
3. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002;38:240-57. (Pubitemid 34136999)
4. Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 2007;167:127-45. (Pubitemid 46214661)
5. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 2011;100:22-32.
6. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012;30:1777-83.
7. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007;25:4066-74. (Pubitemid 47492951)
8. Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 1995;34:313-6.
9. Biaglow JE, Durand RE. The effects of nitrobenzene derivatives on oxygen utilization and radiation response of an in vitro tumor model. Radiat Res 1976;65:529-39.
10. Durand RE, Biaglow JE. Radiosensitization of hypoxic cells of an in vitro tumor model by respiratory inhibitors. Radiat Res 1977;69:359-66. (Pubitemid 8053733)
11. Durand RE, Biaglow JE, Greenstock CL. Effects of sensitizers on cell respiration: III. The effects of hypoxic cell radiosensitizers on oxidative metabolism and the radiation response of an in vitro tumour model. Br J Cancer Suppl 1978;3:150-3. (Pubitemid 8364473)
12. Biaglow JE, Durand RE. The enhanced radiation response of an in vitro tumour model by cyanide released from hydrolysed amygdalin. Int J Radiat Biol Relat Stud Phys Chem Med 1978;33:397-401. (Pubitemid 8322746)
13. Lee I, Glickson JD, Dewhirst MW, Leeper DB, Burd R, Poptani H, et al. Effect of mild hyperglycemia +/-meta-iodo-benzylguanidine on the radiation response of R3230 Ac tumors. Adv Exp Med Biol 2003;530: 177-86. (Pubitemid 37352359)
14. Diepart C, Karroum O, Magat J, Feron O, Verrax J, Calderon PB, et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res 2012;72: 482-90.
15. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012;122:253-70.
16. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348 Pt 3:607-14. (Pubitemid 30410251)
17. Davidoff F. Effects of guanidine derivatives on mitochondrial function. I. Phenethylbiguanide inhibition of respiration in mitochondria from guinea pig and rat tissues. J Clin Invest 1968;47:2331-43.
18. Kreso A, O'Brien CA. Colon cancer stem cells. Curr Protoc Stem Cell Biol 2008;7:3. 1.-13. 1. 12.
19. Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, et al. NKX3. 1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res 2012;18:308-16.
20. Bergstrahl E, Kosanke J. Computerized matching of cases to controls using the greedy matching algorithm with a fixed number of controls per case (gmatch) [SAS macro]. Mayo Clinic Division of Biostatistics; 2003. Available from: http://www.mayo.edu/research/departments-divisions/department-health-sciences- research/division-biomedical-statistics-informatics/software/ locally-written-sas-macros.
21. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007;26:734-53. (Pubitemid 46206593)
22. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009;157:907-21.
23. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
24. Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to antineoplastic effects of metformin in vivo. Oncogene 2011;30:1174-82.
25. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013;23: 143-58.
26. Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, et al. Metformin inhibitsgrowth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 2013;108:2021-32.
27. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, et al. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radio-sensitization of human cancer cells. Int J Radiat Oncol Biol Phys 2010;78:221-9.
28. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2012;2:362.
29. Liu J, Hou M, Yuan T, Yi G, Zhang S, Shao X, et al. Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. Oncol Rep 2012;28:1406-12.
30. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012;18:290-300.
31. Muaddi H, Chowdhury S, Vellanki R, Zamiara P, Koritzinsky M. Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin. Radiother Oncol 2013. [Epub ahead of print.].
32. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994;24:49-57. (Pubitemid 24058005)
33. Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM. Hypofractiona-tion results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 2011;79:1188-95.
34. Brown JM, Diehn M, Loo BW Jr. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 2010;78:323-7.
35. Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 2012;30:1857-63.
36. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013;31:3069-75.
37. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, et al. Metformin use and improved response to therapy in esoph-ageal adenocarcinoma. Acta Oncol 2013;52:1002-9.